Lexicon IBS drug fails in Phase IIa, but Phase IIb study planned
This article was originally published in Scrip
Executive Summary
None of the three doses of Lexicon Pharmaceuticals's LX1033 evaluated in a Phase IIa irritable bowel syndrome (IBS) study provided a statistically significant difference compared with placebo in terms of change in stool consistency, which was the clinical trial's primary endpoint.